Merganser Biotech Inc. Appoints Remy Sukhija As Chief Operating Officer

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Merganser Biotech Inc. ("Merganser"), a preclinical stage biotech company focused on the development of hepcidin mimetic peptides for the treatment of rare hematology and iron overload diseases, announced today that Remy Sukhija has been appointed to the role of Chief Operating Officer, effective immediately.

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.